Widely Used Breast Chemo Regimen Falls Short

<乌鸦传媒 class="mpt-content-deck">— Taxane-cyclophosphamide regimens fail against taxane-anthracycline combinations

by Charles Bankhead, Senior Editor, 乌鸦传媒 June 7, 2016

CHICAGO -- A widely used chemotherapy regimen for early breast cancer encountered a "practice changing failure" in a retrospective survival analysis, reported here at the American Society of Clinical Oncology meeting, involving several clinical trials. In an exclusive 乌鸦传媒 video interview, , of Memorial Sloan Kettering Cancer Center in New York City, explains why breast cancer specialists might have a hard time justifying continued use of taxane-cyclophosphamide chemotherapy regimens for early breast cancer.

Charles Bankhead is senior editor for oncology and also covers urology, dermatology, and ophthalmology. He joined 乌鸦传媒 in 2007.